Search
Isometheptene
go.drugbank.com/drugs/DB06706ApprovedIsometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches.
p-Coumaric acid
go.drugbank.com/drugs/DB04066ExperimentalSynonyms: (E)-p-coumaric acid, (E)-p-hydroxycinnamic acidCategories: Compounds used in a research, industrial, or household settingD-glyceraldehyde 3-phosphate
go.drugbank.com/drugs/DB02263ExperimentalAn aldotriose which is an important intermediate in glycolysis and in tryptophan biosynthesis.
Fluasterone
go.drugbank.com/drugs/DB06250ExperimentalHas antiproliferative effects on HIV-1 and reduces HIV-1 replication.
XTL-6865
go.drugbank.com/drugs/DB06058InvestigationalXTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein. … It is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease.
XL228
go.drugbank.com/drugs/DB05184InvestigationalXL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation
Anecortave acetate
go.drugbank.com/drugs/DB05288InvestigationalAnecortave acetate (Retaane) is an analog of cortisol acetate; among the modifications to the steroid are the removal of the 11ß hydroxyl OH group and an addition of a 21-acetate group. … As a result of these modifications, anecortave acetate lacks the typical antiinflammatory and immunosuppressive properties of glucocorticoids.Alcon Inc. is developing and marketing Retaane.
13-deoxydoxorubicin
go.drugbank.com/drugs/DB05706InvestigationalGPX-100 is an anthracycline anticancer drug that belongs to the family of drugs called antitumor antibiotics.
Zunsemetinib
go.drugbank.com/drugs/DB16502InvestigationalAdditionally, ATI-450 was studied in a terminated trial (NCT05511519) to treat patients with psoriatic arthritis. … Zunsemetinib is being investigated in a new clinical trial (NCT06374459) for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer with bone metastasis.